Waxman Renews Push For FDA Examination Of Phenylephrine Efficacy
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's decision to sell Claritin-D behind the counter rather than reformulate with the nasal decongestant phenylephrine has prompted Rep. Henry Waxman (D-Calif.) to renew his request for an FDA review of the ingredient's efficacy
You may also be interested in...
Asking Advisors About Phenylephrine Efficacy May Portend FDA Taking Streamlined Monograph Steps
NDAC will discuss whether data supports oral phenylephrine’s GRASE as nasal decongestant. Potential for removing phenylephrine from monograph could be linked to restricting nonprescription pseudoephedrine drugs to behind-the-counter sales since 2006 and overhaul of FDA monograph program authorized in 2020.
From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA
The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year
Wyeth Touts PE Efficacy Claims In Comments To FDA
A letter to the editor in the July Journal of Allergy & Clinical Immunology questioning phenylephrine efficacy inappropriately downplayed positive data in favor of negative studies, Wyeth Consumer Healthcare states in comments submitted to FDA Nov. 16